SB743921: Potent KSP Inhibitor for Cancer Research

Executive Summary: SB743921 is a potent and selective inhibitor of the kinesin spindle protein (KSP), exhibiting a Ki of 0.1 nM for human KSP and 0.12 nM for mouse KSP (APExBIO, SB743921 product page). It induces robust cell cycle arrest in mitosis, leading to apoptosis in various human cancer lines, with reported IC50 values between 0.02 and 1.7 nM (Schwartz 2022, DOI). SB743921 demonstrates efficacy in multiple xenograft tumor models, including Colo205, MCF-7, and P388 leukemia. The compound is chemically defined as N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxochromen-2-yl)-2-methylpropyl]-4-methylbenzamide hydrochloride, with a molecular weight of 553.53 g/mol. SB743921 is insoluble in water but highly soluble in DMSO (≥55.4 mg/mL) and ethanol (≥11.2 mg/mL, ultrasonic assistance), and is intended exclusively for research use (APExBIO, SB743921).

Biological Rationale

Kinesin spindle protein (KSP, also known as Eg5 or KIF11) is a mitotic kinesin essential for the formation of bipolar spindles during mitosis. Inhibition of KSP disrupts spindle assembly, leading to mitotic arrest and programmed cell death (apoptosis) in proliferating cells. This mechanism is particularly relevant in rapidly dividing cancer cells, where precise control of mitosis is critical for tumor growth. Targeting the KSP pathway offers a non-tubulin, mitosis-specific approach that avoids some of the neuropathic side effects associated with classic tubulin modulators (Schwartz 2022, DOI). SB743921 exemplifies the class of mitotic kinesin inhibitors designed for selective targeting of this pathway.

Mechanism of Action of SB743921

SB743921 binds selectively to the motor domain of human and mouse KSP, inhibiting ATPase activity with Ki values of 0.1 nM and 0.12 nM, respectively (APExBIO SB743921). The inhibition prevents the sliding of microtubules necessary for bipolar spindle formation, resulting in monopolar spindle assembly. This triggers prolonged mitotic arrest at the metaphase/anaphase transition. Prolonged mitotic arrest activates apoptotic signaling cascades, culminating in cell death. Notably, SB743921 does not exhibit significant affinity for other kinesin family members, ensuring specificity for KSP-mediated processes (APExBIO, product documentation).

Evidence & Benchmarks

• SB743921 exhibits nanomolar potency in anti-proliferative assays across SKOV3, Colo205, MV522, and MX1 cancer cell lines with IC50 values ranging from 0.02 nM to 1.7 nM (Schwartz 2022, DOI).
• Demonstrated efficacy in multiple human tumor xenograft models, including Colo205, MCF-7, SK-MES, H69, OVCAR-3, HT-29, MDA-MB-231, A2780, and P388 leukemia, confirming in vivo relevance (Schwartz 2022, DOI).
• Induces mitotic arrest and apoptosis, distinguishable from tubulin-targeting agents by the formation of monopolar (not depolymerized) spindles (cellron.net analysis).
• High selectivity for KSP, with negligible inhibition of other kinesins in enzymatic profiling (APExBIO, SB743921 profile).
• Stable as a solid at -20°C; solutions should be prepared freshly to ensure activity (APExBIO, storage protocol).

This article extends the mechanistic detail provided by 'SB743921: Potent KSP Inhibitor for Cancer Research Workflows' by focusing on quantitative potency data and practical workflow integration.

Applications, Limits & Misconceptions

SB743921 is used in preclinical cancer research to dissect mitotic mechanisms, benchmark anti-proliferative agents, and validate the KSP pathway for targeted therapies. Its nanomolar potency allows for precise titration in cell cycle and apoptosis assays. The compound's selectivity profile makes it suitable for studies where off-target kinesin inhibition would confound results. SB743921 is not recommended for clinical, diagnostic, or medical use.

Common Pitfalls or Misconceptions

• SB743921 is not suitable for long-term aqueous solution storage; activity declines rapidly (>24 hours) even at 4°C.
• It does not inhibit tubulin polymerization and should not be used as a substitute for tubulin-targeting drugs.
• Off-target effects on non-KSP kinesins are negligible, but it should not be used to model pan-kinesin inhibition.
• Efficacy in non-dividing (quiescent) cells is minimal; the mechanism is mitosis-specific.
• For in vivo use, formulation and pharmacokinetics must be validated per model; insolubility in water can limit some routes of administration.

This piece clarifies the boundaries discussed in 'SB743921 and the Future of Mitotic Kinesin Inhibition', emphasizing experimental design considerations for SB743921 versus other KSP inhibitors.

Workflow Integration & Parameters

SB743921 (SKU B1590) is supplied as a chemically defined solid. For typical in vitro experiments, dissolve in DMSO to ≥55.4 mg/mL or ethanol to ≥11.2 mg/mL with ultrasonic assistance. Prepare working solutions immediately before use. Store the solid at -20°C; avoid repeated freeze-thaw cycles. For cell-based assays, dose-response curves should start at 0.01 nM to 10 nM to bracket IC50 values for sensitive lines (Schwartz 2022, DOI). For in vivo studies, refer to xenograft dosing protocols and solubilization recommendations as published by APExBIO (product page). For detailed troubleshooting and workflow strategies, see 'SB743921 (SKU B1590): Practical Solutions for Reliable Mitotic Inhibition', which this article updates with refined stability and dosing guidance.

Conclusion & Outlook

SB743921 is a validated, potent, and selective tool for probing the kinesin spindle protein pathway in cancer research. Its well-characterized mechanism and robust anti-proliferative profile make it a standard for in vitro and in vivo studies. As a research-use-only reagent provided by APExBIO, SB743921 enables the precise analysis of mitotic kinesin inhibition and supports the development of next-generation anti-mitotic therapeutics. Continued benchmarking in diverse tumor models will further define its translational potential.